Nxera Pharma Co., Ltd.
SOLTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,835,000 | $12,766,000 | $15,569,000 | $17,712,000 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Cost of Goods Sold | $7,616,000 | $3,102,000 | $926,000 | $933,000 |
| Gross Profit | $21,219,000 | $9,664,000 | $14,643,000 | $16,779,000 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| R&D Expenses | $11,816,000 | $10,075,000 | $7,454,000 | $5,931,000 |
| G&A Expenses | $16,015,000 | $9,965,000 | $4,377,000 | $3,940,000 |
| SG&A Expenses | $16,015,000 | $9,965,000 | $4,377,000 | $3,940,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,189,000 | -$850,000 | -$624,000 | $3,133,000 |
| Operating Expenses | $26,642,000 | $19,190,000 | $11,207,000 | $13,004,000 |
| Operating Income | -$5,423,000 | -$9,526,000 | $3,436,000 | $3,775,000 |
| % Margin | -18.8% | -74.6% | 22.1% | 21.3% |
| Other Income/Exp. Net | $761,000 | -$1,154,000 | -$2,358,000 | -$3,342,000 |
| Pre-Tax Income | -$4,662,000 | -$10,680,000 | $1,078,000 | $433,000 |
| Tax Expense | $176,000 | -$3,487,000 | $696,000 | -$584,000 |
| Net Income | -$4,838,000 | -$7,193,000 | $382,000 | $1,017,000 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS | -53.95 | -87.18 | 4.67 | 12.53 |
| % Growth | 38.1% | -1,966.8% | -62.7% | – |
| EPS Diluted | -53.95 | -87.17 | 4.63 | 12.4 |
| Weighted Avg Shares Out | 89,676 | 82,507 | 81,785 | 81,187 |
| Weighted Avg Shares Out Dil | 89,676 | 82,517 | 82,590 | 82,006 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,544,000 | $1,341,000 | $663,000 | $199,000 |
| Interest Expense | $783,000 | $2,495,000 | $756,000 | $3,797,000 |
| Depreciation & Amortization | $3,984,000 | $2,478,000 | $1,345,000 | $1,278,000 |
| EBITDA | $105,000 | -$5,707,000 | $3,179,000 | $8,188,000 |
| % Margin | 0.4% | -44.7% | 20.4% | 46.2% |